By Nick Johnson (Apyx) In 2023 Shareholder News, RenuvionPosted February 1, 2023APYX MEDICAL CORPORATION ANNOUNCES FDA 510(K) SUBMISSION FOR THE USE OF THE RENUVION APR HANDPIECE FOR THE COAGULATION OF SUBCUTANEOUS SOFT TISSUES WHERE NEEDED, FOLLOWING LIPOSUCTION READ MORE
By apyxmedical In 2023 Shareholder News, RenuvionPosted January 25, 2023APYX MEDICAL CORPORATION LAUNCHES NEW ‘APYX ONE CONSOLE’ FOR COSMETIC SURGICAL PROCEDURES IN THE UNITED STATES READ MORE
By apyxmedical In 2022 Shareholder News, 2023 Shareholder News, J-Plasma, RenuvionPosted January 10, 2023APYX MEDICAL CORPORATION REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2022 REVENUE RESULTS READ MORE
By apyxmedical In 2023 Shareholder News, J-Plasma, RenuvionPosted January 3, 2023APYX MEDICAL CORPORATION EMBARKS ON INAUGURAL BRAND CAMPAIGN FOR RENUVION READ MORE
